Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

Submitted by amarin on Wed, 05/03/2023 - 11:01
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA ® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

Submitted by amarin on Wed, 05/03/2023 - 11:00
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA ® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Submitted by amarin on Wed, 04/19/2023 - 12:01
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s first quarter 2023

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

Submitted by amarin on Mon, 04/17/2023 - 11:00
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S.